ITEM 7.01 REGULATION FD



On January 3, 2022, Envista Holdings Corporation (the "Company") issued a press
release announcing the closing of the previously disclosed divestiture of its
KaVo dental treatment unit and instrument business (the "KaVo Treatment Unit and
Instrument Business"). A copy of the press release is furnished hereto as
Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference in
this Item 7.01.

The information included or incorporated by reference in this Item 7.01 is being
furnished to the Securities and Exchange Commission (the "SEC") and shall not be
deemed "filed" for purposes of Section 18 of the Exchange Act or otherwise
subject to the liabilities of that section, nor shall it be deemed incorporated
by reference in any filing under the Securities Act or the Exchange Act, except
as shall be expressly set forth by specific reference in such filing.

ITEM 8.01 OTHER EVENTS



On December 31, 2021, pursuant to the previously disclosed master sale and
purchase agreement (the "Purchase Agreement"), dated September 7, 2021, by and
among the Company, planmeca Verwaltungs GmbH, Germany ("Planmeca"), and Planmeca
Oy, a privately-held Finnish company, as guarantor, the Company closed the
divestiture of its KaVo Treatment Unit and Instrument Business (the
"Divestiture"). In connection with the Divestiture, Planmeca paid $317.3 million
in cash at closing, which remains subject to certain adjustments. The Company
expects to receive an earnout payment of $30 million in the first quarter of
2022, plus an estimated $36.2 million in adjustments under the Purchase
Agreement in the second quarter of 2022.

On December 30, 2021, the Company entered into an amendment to the Purchase
Agreement (the "Amendment"), providing that the transfer of assets in Russia,
China and Brazil (the "Relevant Jurisdictions") will be deferred until the
purchaser has formed entities for such transfer of assets in each such Relevant
Jurisdiction and the applicable asset transfer agreement can be executed and
consummated (each such asset transfer, a "Deferred Local Closing"). Except for
the implementation of the Deferred Local Closings and related matters regarding
the assets in the Relevant Jurisdictions, the provisions, terms and conditions
of the Purchase Agreement are not materially amended by the Amendment. The
Amendment did not alter the preliminary purchase price that Planmeca paid to the
Company upon the closing of the Divestiture.

The foregoing description of the Amendment does not purport to be complete and
is subject to, and qualified in its entirety by, the full text of the Amendment
which will be filed by the Company with the Company's Annual Report on Form 10-K
for the year ended December 31, 2021. The disclosure set forth in this Item 8.01
is qualified in its entirety by reference to the Amendment and to the Purchase
Agreement, which is filed as Exhibit 10.1 to the Company's Quarterly Report on
Form 10-Q filed with the SEC on November 3, 2021, which is incorporated herein
by reference.


ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS
(d) Exhibits.
   Exhibit No.            Description
       99.1                 Press Release dated January 3, 2022
       104                Cover Page Interactive Data File (embedded within the Inline XBRL document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses